Documents


Explore the latest documents from the company, including regulatory filings and corporate disclosures that offer insight into company performance and strategy. Use these resources to support informed investment decisions.
2026
Earnings, Q3 FY2026
Stable Q3 results face intensified TDAPA pressure and a EUR 300m–EUR 350m 2027 headwind.
Earnings, Q2 FY2026
Operating income up 23% with margin gains, strong cash flow, and 2026 guidance confirmed.
AGM 2026
Strong financials, new strategy, leadership changes, and innovation drive future growth.
Investor presentation
Q1 2026 saw robust growth, margin expansion, and accelerated innovation in kidney care.
Earnings, Q1 FY2026
Q1 saw strong growth, margin expansion, and strategic execution, with stable 2026 outlook.
Investor presentation
Record profitability, innovation, and capital returns position the group for industry-leading growth.
44th Annual J.P. Morgan Healthcare Conference
High-volume HDF rollout and strong financials drive growth, with 2026 as a key transition year.
2025
Earnings, Q4 FY2025
Annual
Record 2025 profitability and cash flow set a high base for a transition year in 2026.
Earnings, Q4 FY2025
2025 saw robust growth and profitability, with 2026 focused on HDF rollout and margin stability.
Earnings, Q3 FY2025
Q3 saw robust revenue and earnings growth, margin expansion, and strong execution across all segments.
Earnings, Q2 FY2025
Strong Q2 growth, margin expansion, and robust cash flow drive share buyback and guidance confirmation.
Investor Presentation
CMD 2025
AGM 2025
Earnings, Q1 FY2025
43rd Annual J.P. Morgan Healthcare Conference
2024
Earnings, Q4 FY2024
Annual
Earnings, Q3 FY2024
Expert Call
Earnings, Q2 FY2024
Status Update
Earnings, Q1 FY2024
2023
Earnings, Q4 FY2023
Annual
Earnings, Q4 FY2023